{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T19:10:18Z","timestamp":1739560218540,"version":"3.37.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"DOI":"10.1007\/s00423-025-03623-w","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:33:26Z","timestamp":1739558006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of three subtypes of thyroid cancer based on IFN-\u03b3-related genes to reveal their prognostic characteristics"],"prefix":"10.1007","volume":"410","author":[{"given":"Fang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"3623_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-55031-8_10","volume":"1287","author":"R Guenter","year":"2021","unstructured":"Guenter R, Patel Z, Chen H (2021) Notch signaling in thyroid cancer. Adv Exp Med Biol 1287:155\u2013168","journal-title":"Adv Exp Med Biol"},{"key":"3623_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12020-022-03274-7","volume":"80","author":"J Huang","year":"2023","unstructured":"Huang J, Ngai CH, Deng Y, Pun CN, Lok V, Zhang L et al (2023) Incidence and mortality of thyroid cancer in 50 countries: a joinpoint regression analysis of global trends. Endocrine 80:355\u2013365","journal-title":"Endocrine"},{"key":"3623_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C et al (2022) The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol 10:264\u2013272","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3623_CR4","doi-asserted-by":"publisher","first-page":"e2246311","DOI":"10.1001\/jamanetworkopen.2022.46311","volume":"5","author":"X Feng","year":"2022","unstructured":"Feng X, Wang F, Yang W, Zheng Y, Liu C, Huang L et al (2022) Association between genetic risk, adherence to healthy lifestyle behavior, and thyroid cancer risk. JAMA Netw Open 5:e2246311","journal-title":"JAMA Netw Open"},{"key":"3623_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41574-019-0263-x","volume":"16","author":"J Kim","year":"2020","unstructured":"Kim J, Gosnell JE, Roman SA (2020) Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol 16:17\u201329","journal-title":"Nat Rev Endocrinol"},{"key":"3623_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clon.2011.01.509","volume":"23","author":"C Maenhaut","year":"2011","unstructured":"Maenhaut C, Detours V, Dom G, Handkiewicz-Junak D, Oczko-Wojciechowska M, Jarzab B (2011) Gene expression profiles for radiation-induced thyroid cancer. Clin Oncol (R Coll Radiol) 23:282\u2013288","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3623_CR7","doi-asserted-by":"crossref","unstructured":"Hu J, Yuan IJ, Mirshahidi S, Simental A, Lee SC, Yuan X (2021) Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for targeting therapy. Int J Mol Sci 22","DOI":"10.3390\/ijms22041950"},{"key":"3623_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ijc.33690","volume":"149","author":"F Nabhan","year":"2021","unstructured":"Nabhan F, Dedhia PH, Ringel MD (2021) Thyroid cancer, recent advances in diagnosis and therapy. Int J Cancer 149:984\u2013992","journal-title":"Int J Cancer"},{"key":"3623_CR9","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013. JAMA 317:1338\u20131348","journal-title":"JAMA"},{"key":"3623_CR10","doi-asserted-by":"publisher","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Wu M, Liu Z (2023) Dysregulation in IFN-gamma signaling and response: the barricade to tumor immunotherapy. Front Immunol 14:1190333","journal-title":"Front Immunol"},{"key":"3623_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA (2022) Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22:158\u2013172","journal-title":"Nat Rev Immunol"},{"key":"3623_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-14-0098","volume":"3","author":"H Matsushita","year":"2015","unstructured":"Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M et al (2015) Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNgamma-dependent cell-cycle arrest. Cancer Immunol Res 3:26\u201336","journal-title":"Cancer Immunol Res"},{"key":"3623_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F, Cardoso AP, Goncalves RM, Serre K, Oliveira MJ (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 9:847","journal-title":"Front Immunol"},{"key":"3623_CR14","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1038\/s41467-022-31932-x","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Du M, Yuan Z, Chen Z, Yan F (2022) Spatiotemporal control of engineered bacteria to express interferon-gamma by focused ultrasound for tumor immunotherapy. Nat Commun 13:4468","journal-title":"Nat Commun"},{"key":"3623_CR15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41556-021-00733-7","volume":"23","author":"S Singh","year":"2021","unstructured":"Singh S, Kumar S, Srivastava RK, Nandi A, Thacker G, Murali H et al (2021) Author correction: loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-gamma signalling. Nat Cell Biol 23:1048","journal-title":"Nat Cell Biol"},{"key":"3623_CR16","doi-asserted-by":"crossref","unstructured":"Khan S, Mahalingam R, Sen S, Martinez-Ledesma E, Khan A, Gandy K et al (2021) Intrinsic interferon signaling regulates the cell death and mesenchymal phenotype of glioblastoma stem cells. Cancers (Basel) 13","DOI":"10.3390\/cancers13215284"},{"key":"3623_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trecan.2022.09.003","volume":"9","author":"H Cheon","year":"2023","unstructured":"Cheon H, Wang Y, Wightman SM, Jackson MW, Stark GR (2023) How cancer cells make and respond to interferon-I. Trends Cancer 9:83\u201392","journal-title":"Trends Cancer"},{"key":"3623_CR18","doi-asserted-by":"publisher","first-page":"11381","DOI":"10.18632\/aging.202831","volume":"13","author":"B Yao","year":"2021","unstructured":"Yao B, Wang L, Wang H, Bao J, Li Q, Yu F et al (2021) Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma. Aging 13:11381\u201311410","journal-title":"Aging"},{"key":"3623_CR19","doi-asserted-by":"publisher","first-page":"994019","DOI":"10.3389\/fimmu.2022.994019","volume":"13","author":"X Qu","year":"2022","unstructured":"Qu X, Zhao X, Lin K, Wang N, Li X, Li S et al (2022) M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma. Front Immunol 13:994019","journal-title":"Front Immunol"},{"key":"3623_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202\u2013206","journal-title":"Nat Genet"},{"key":"3623_CR21","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P et al (2022) Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open 7:100336","journal-title":"ESMO Open"},{"key":"3623_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13073-022-01024-y","volume":"14","author":"J Long","year":"2022","unstructured":"Long J, Wang D, Wang A, Chen P, Lin Y, Bian J et al (2022) A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Med 14:20","journal-title":"Genome Med"},{"key":"3623_CR23","doi-asserted-by":"publisher","first-page":"895428","DOI":"10.3389\/fendo.2022.895428","volume":"13","author":"Y Xia","year":"2022","unstructured":"Xia Y, Jiang X, Huang Y, Liu Q, Huang Y, Zhang B et al (2022) Construction of a tumor immune microenvironment-related prognostic model in BRAF-mutated papillary thyroid cancer. Front Endocrinol (Lausanne) 13:895428","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3623_CR24","doi-asserted-by":"publisher","first-page":"e24444","DOI":"10.1002\/jcla.24444","volume":"36","author":"C Wang","year":"2022","unstructured":"Wang C, Pan D (2022) Mutation patterns and prognostic analysis of BRAF\/KRAS\/PIK3CA in colorectal cancer. J Clin Lab Anal 36:e24444","journal-title":"J Clin Lab Anal"},{"key":"3623_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12876-021-01671-2","volume":"21","author":"A Kuerbanjiang","year":"2021","unstructured":"Kuerbanjiang A, Maimaituerxun M, Zhang Y, Li Y, Cui G, Abuduhabaier A et al (2021) V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients. BMC Gastroenterol 21:86","journal-title":"BMC Gastroenterol"},{"key":"3623_CR26","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","volume":"27","author":"SD Richman","year":"2009","unstructured":"Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931\u20135937","journal-title":"J Clin Oncol"},{"key":"3623_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2478\/raon-2019-0033","volume":"53","author":"VA Afrasanie","year":"2019","unstructured":"Afrasanie VA, Marinca MV, Alexa-Stratulat T, Gafton B, Paduraru M, Adavidoaiei AM et al (2019) KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol 53:265\u2013274","journal-title":"Radiol Oncol"},{"key":"3623_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2022.12.027","volume":"182","author":"X Wang","year":"2023","unstructured":"Wang X, Wu X, Yang Y, Xu W, Tian H, Lian B et al (2023) Apatinib combined with camrelizumab in advanced acral melanoma patients: an open-label, single-arm phase 2 trial. Eur J Cancer 182:57\u201365","journal-title":"Eur J Cancer"},{"key":"3623_CR29","doi-asserted-by":"publisher","first-page":"691032","DOI":"10.3389\/fimmu.2021.691032","volume":"12","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wang X, Chi Z, Sheng X, Kong Y, Mao L et al (2021) Association of NRAS mutation with clinical outcomes of anti-PD-1 monotherapy in advanced melanoma: a pooled analysis of four Asian clinical trials. Front Immunol 12:691032","journal-title":"Front Immunol"},{"key":"3623_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","volume":"1182","author":"CH Miller","year":"2009","unstructured":"Miller CH, Maher SG, Young HA (2009) Clinical use of interferon-gamma. Ann N Y Acad Sci 1182:69\u201379","journal-title":"Ann N Y Acad Sci"},{"key":"3623_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM (2020) Natural killer cells in cancer biology and therapy. Mol Cancer 19:120","journal-title":"Mol Cancer"},{"key":"3623_CR32","doi-asserted-by":"publisher","first-page":"e51329","DOI":"10.15252\/embr.202051329","volume":"22","author":"Z Chen","year":"2021","unstructured":"Chen Z, Yang Y, Neo SY, Shi H, Chen Y, Wagner AK et al (2021) Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+) \/CD54(+) NK cells. EMBO Rep 22:e51329","journal-title":"EMBO Rep"},{"key":"3623_CR33","doi-asserted-by":"crossref","unstructured":"Boutilier AJ, Elsawa SF (2021) Macrophage polarization states in the tumor microenvironment. Int J Mol Sci 22","DOI":"10.3390\/ijms22136995"},{"key":"3623_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14:717\u2013734","journal-title":"Nat Rev Clin Oncol"},{"key":"3623_CR35","first-page":"293","volume":"7","author":"DH Josephs","year":"2015","unstructured":"Josephs DH, Bax HJ, Karagiannis SN (2015) Tumour-associated macrophage polarisation and re-education with immunotherapy. Front Biosci (Elite Ed) 7:293\u2013308","journal-title":"Front Biosci (Elite Ed)"},{"key":"3623_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462\u2013472","journal-title":"Cancer Cell"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-025-03623-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:33:30Z","timestamp":1739558010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-025-03623-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1007\/s00423-025-03623-w","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}